关注乳腺癌伴随疾病全方位管理之非酒精性脂肪性肝病的管理  

Strengthening the comprehensive management of concomitant diseases of breast cancer:non-alcoholic fatty liver disease

作　　者：田申 伍娟(综述) 孔令泉[1] 吴凯南(审校)[1] TIAN Shen;WU Juan;KONG Ling-quan(Department of Endocrine and Breast Surgery,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院内分泌乳腺外科,重庆400016

出　　处：《中国临床新医学》2020年第8期836-840,共5页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

摘　　要：非酒精性脂肪性肝病在乳腺癌患者化疗及内分泌治疗期间有较高的发生率,它是患者肝功能损伤或肝酶异常的常见原因,并影响乳腺癌患者的治疗和预后,但其防治尚未引起足够的重视。该文将系统阐述乳腺癌患者辅助治疗期间非酒精性脂肪性肝病的管理与防治,以提高对其认识,并进一步改善乳腺癌患者的生存质量和预后。Non-alcoholic fatty liver disease(NAFLD)has a high incidence in breast cancer patients during chemotherapy and endocrine therapy.NAFLD is a common case of hepatic dysfunction and abnormal liver enzymes,and therefore affects the therapy and prognosis of breast cancer patients.However,the prevention and treatment of NAFLD has not attracted enough attention.In this paper,we systematically review the management,prevention and treatment of NAFLD in breast cancer patients during adjuvant therapy to raise awareness of NAFLD and further improve the quality of life and prognosis of breast cancer patients.

关 键 词：乳腺癌 乳腺癌伴随疾病 非酒精性脂肪肝 乳腺肿瘤肝病学 代谢相关脂肪性肝病 

分 类 号：R736[医药卫生—肿瘤] R657[医药卫生—临床医学]